With full ownership now complete, all Flyte operations, assets and economics are fully consolidated within Catheter Precision, providing direct exposure to operating performance and long-term equity value creation.

The FAA Part 135 operator welcomes a 19.98% strategic stake to support scalable fleet growth and AI-enabled optimisation.

The aircraft is optimised for regional missions in the 300–400nm range, where time savings, airport access and operating efficiency matter most. These include the Northeast and Florida corridors and secondary city pairs.